Navigating the Maze: The EU Pharma Legislation Review and its Implications

By Staff Writer

November 28, 2023

The EU Pharma Legislation Review: A Hot Topic

The buzz at the ISPOR Europe 2023 conference in Copenhagen was all about the proposed EU pharma legislation review. This legislation, proposed at a potentially turbulent time, aims to reshape the healthcare landscape in Europe. But has encountered significant resistance from the pharmaceutical industry. The industry is also grappling with the simultaneous implementation of the joint Health Technology Assessment regulation (HTAR).

Balancing Industry and Health Policies: A Complex Task

The panel at the conference highlighted the difficulty of balancing industry and health policies, particularly concerning affordability and sustainability. They concurred that the proposed legislation did little to rectify the misalignment issues, which are further complicated by geopolitical considerations and a lack of clarity in the legislation review.

Perspectives on the Legislation: Industry and Policymaker

Neil Grubert, an independent Global Market Access Consultant, representing the industry perspective, expressed concern about the potential pressure on joint clinical assessment (JCA) timelines due to the expedited timelines proposed in the review. He highlighted the need to consider the global context, particularly as Europe has lost ground to the U.S. in R&D spend and launches.

Yannis Natsis, Director of the European Social Insurance Platform (ESIP), termed the interplay between industry policy and health policy as “complex”. He criticised the legislation for being rushed and for having weak evidence requirements, leading to high prices for certain medicines. He called for more interaction and collaboration between HTA, regulators, payers, and the industry.

The Payer Perspective and Future Implications

Johan Pontén, International Co-ordinator at Sweden’s Dental and Pharmaceutical Benefits Agency, (TLV), expressed concern about the increasing expenditure and drug prices, coupled with lower evidence on effectiveness being presented for assessments. He argued for the compulsory requirement to conduct a comparative study instead of the proposed incentive.

 

The panel agreed that the lack of clarity in the legislation is causing confusion about potential consequences. While the legislation could lead to significant changes, stakeholders are currently in a grey zone. They are anticipating the switch without the necessary tools or knowledge to take precautionary actions.

Reference url

Recent Posts

masitinib prostate cancer trial
        

Masitinib Prostate Cancer Trial Gains FDA and EMA Approval for Phase 3 Study

🚀 What’s the next big thing in prostate cancer treatment?

The recent FDA and EMA authorizations for the masitinib prostate cancer trial could revolutionize care for metastatic castrate-resistant prostate cancer (mCRPC). This groundbreaking study employs a biomarker-driven strategy to optimize treatment outcomes for patients like never before!

Dive into the full article to explore the implications of this targeted therapy and how it may change the future of precision medicine in oncology.

#SyenzaNews #Oncology #PrecisionMedicine #HealthTech

BEBT-908 DLBCL treatment
        

BEBT-908 DLBCL Treatment: A Milestone Approval for a First-in-Class Dual Inhibitor in China

🚀 Are we on the brink of a revolution in DLBCL treatment?

The recent conditional approval of **BEBT-908** by China’s National Medical Products Administration is not just a milestone for oncology, but potentially a game-changer for adults battling relapsed or refractory diffuse large B-cell lymphoma. With its dual-target mechanism, this first-in-class therapy offers promising efficacy and a well-thought-out access strategy that could reshape treatment standards.

Dive into the full article to discover how BEBT-908 is setting new benchmarks in both clinical outcomes and healthcare affordability.

#SyenzaNews #oncology #pharmaceuticals #MarketAccess

AI Cost Implications
    

AI Clinician in Pediatric ICU: A Review and HEOR Perspective

🤖 What could AI Clinician support mean for pediatric ICU care?

A new collaboration between Imperial College London and CHOC is developing an AI system to guide treatment decisions in PICUs. This article reviews the initiative and examines its broader health system implications—offering a Health Economics and Outcomes Research (HEOR) perspective on how AI may shape efficiency, equity, and value in critical care.

Read on to explore how clinical innovation intersects with healthcare economics.

#SyenzaNews #AIinHealthcare #HEOR #PediatricCare #HealthInnovation #PICU

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.